Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
Vienna - Austria, 3 July 2020 - The economic downturn and the effects of the
corona crisis lead to opposing developments in the Industrial and Medical
sectors of the publicly listed Semperit Group: in the business for medical
protective gloves, a significant increase in demand and a strong rise in price
levels has been observed since the outbreak of the corona crisis. Against this
background, and also in view of the improved operating performance, the results
of the Medical sector will be significantly higher in 2020 compared to the
previous year's level.
The emerging effects of the global pandemic are considered to be limitedly
sustainable. For this reason, the strategic landmark decision of 28 January
2020, according to which Semperit will focus on the industrial rubber business
in the future and separate from the medical business, is still valid, regardless
of the recent developments observed in the wake of the corona crisis.
The Industrial sector was hit by the global recession, which has intensified in
recent months due to the worldwide lockdown. The results of the Industrial
Sector of the current financial year will therefore be noticeably below the
previous year's level. However, the positive effects from the medical business
in the foreseeable future will significantly compensate for this decline.
Based on current figures, EBITDA of the Semperit Group for the full year is
currently expected to be significantly higher than the previous year's figure
(2019: EUR 67.8 million). However, the currently unforeseeable duration of the
corona crisis and its impact on the global economy make it difficult to provide
reliable forecasts regarding financial effects on the Semperit Group.
In view of the developments described above, Semperit reviews the existence of
indicators for a reversal of past impairment losses or impairment losses in the
Medical or the Industrial sector respectively. The amount of any value
adjustments will be announced at the latest upon publication of the half-year
Taking this into account, the Semperit Group currently expects an EBIT of EUR
110.0 to 160.0 million (2019: EUR -16.5 million) for the full year 2020 -
depending particularly on the further development of the price level for medical
protective gloves and the sufficient availability of raw materials for their
end of announcement euro adhoc
issuer: Semperit AG Holding
phone: +43 1 79 777-310
FAX: +43 1 79 777-602
indexes: WBI, ATX GP, ATX PRIME
Digital press kit: http://www.ots.at/pressemappe/2918/aom
Martin Füllenbach, Vorstandsvorsitzender der Semperit AG Holding, Gerfried Eder, Managing Director/Director Sales/Semperflex; Credit: Semperit Group
, (© Aussender) >> Öffnen auf photaq.com
Aktien auf dem Radar:Marinomed Biotech, Semperit, Wienerberger, Polytec, SBO, Warimpex, Agrana, Immofinanz, RBI, ATX, ATX Prime, Erste Group, Uniqa, AMS, UBM, Addiko Bank, Andritz, Frauenthal, Palfinger, Pierer Mobility AG, SW Umwelttechnik, Wolford, Porr, Frequentis, Rosenbauer, EVN.
Die Warimpex Finanz- und Beteiligungs AG ist eine Immobilienentwicklungs- und Investmentgesellschaft. Im Fokus der Geschäftsaktivitäten stehen der Betrieb und die Errichtung von Hotels in CEE. Darüber hinaus entwickelt Warimpex auch Bürohäuser und andere Immobilien.
>> Besuchen Sie 56 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER